Levonorgestrel News and Research

RSS

Hormonal contraception may increase susceptibility of women to genital infection

Women account for approximately half of all individuals living with HIV worldwide, and researchers wanted to identify the risk factors that increase susceptibility of women to genital infection.

20 Apr 2016

New study provides biological explanation for how DMPA increases risk of HIV infection

In recent years, evidence has been building that injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera or DMPA) is associated with an increased risk of HIV infection. Now a study published in the September 1st issue of mBio, an online open-access journal of the American Society for Microbiology, provides a biological explanation for the phenomenon.

2 Sep 2015

Mylan releases generic version of Seasonale Tablets in the U.S.

Mylan N.V. today announced the U.S. launch of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, which is the generic version of Teva's Seasonale Tablets. Mylan's partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

5 May 2015

Alternative treatment options for uterine fibroids

A 47-year-old African-American woman has heavy menstrual bleeding and iron-deficiency anemia. She reports the frequent need to urinate during the night and throughout the day. A colonoscopy is negative and an ultrasonography shows a modestly enlarged uterus with three uterine fibroids, noncancerous growths of the uterus.

24 Apr 2015

Contraception access: an interview with Pamela Weir, Chief Operating Officer, Medicines360

One of the key barriers for women to receiving highly effective and safe contraception is access, because of cost. With LILETTA™ women will have expanded access to an available IUD that is safe and effective when they need or want it...

From Medicines 360 7 Apr 2015

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

Bayer expands patient assistance program for intrauterine devices

Bayer HealthCare Pharmaceuticals Inc. today announced the expansion of its patient assistance program for intrauterine devices (IUD). The ARCH (Access and Resources for Contraceptive Health) program will provide Skyla (levonorgestrel-releasing intrauterine system) 13.5 mg and Mirena (levonorgestrel-releasing intrauterine system) 52 mg to low-income women who meet eligibility criteria.

23 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

Study: IUDs, contraceptive implants remain highly effective one year beyond approved duration of use

New research indicates that hormonal intrauterine devices (IUDs) and contraceptive implants remain highly effective one year beyond their approved duration of use, according to a study at Washington University School of Medicine in St. Louis.

6 Feb 2015

Study finds unnecessary hysterectomy in 1 out of 5 cases

It is estimated that one in three women in the United States will have had a hysterectomy by the age of 60. Although the numbers of hysterectomies are decreasing, a new study of more than three thousand women in Michigan who underwent hysterectomy for benign indications reveals that alternatives to hysterectomy are being underused and that treatment guidelines are often not followed.

7 Jan 2015

FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures.

20 Oct 2014

Researchers recommend iron supplementation to women with heavy menstrual bleeding

A study by researchers from Finland found that diagnosis and treatment of anemia is important to improve quality of life among women with heavy periods.

9 Jun 2014

Survey finds counterfeit and defective emergency contraceptives in Peru

A survey of emergency contraceptive pills in Peru found that 28 percent of the batches studied were either of substandard quality or falsified. Many pills released the active ingredient too slowly. Others had the wrong active ingredient. One batch had no active ingredient at all.

20 Apr 2014

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual American Epilepsy Society (AES) meeting, taking place in Washington, D.C. from December 6 – 10.

6 Dec 2013

Two intrauterine contraceptive systems safe and effective in preventing pregnancies

In a finding that could expand the use of one of the most effective forms of birth control, two intrauterine contraceptive systems that had lower doses of the contraceptive hormone, levonorgestrel, were found to be safe and effective in preventing pregnancies, according to an international study that included researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed).

5 Dec 2013

Researchers create intravaginal ring using MPT to protect women from HIV and unintended pregnancy

A new intravaginal ring (IVR) has been developed for the sustained 90-day co-delivery of tenofovir and levonorgestrel, an anti-human immunodeficiency virus (HIV) drug and a contraceptive.

13 Nov 2013

IPM receives US$40M from USAID to advance new HIV prevention tools for women

The International Partnership for Microbicides (IPM) announced today that it has received two competitive five-year awards with a combined US$40 million ceiling from the US Agency for International Development (USAID).

23 Oct 2013

Quartette tablets now available in U.S. for prevention of pregnancy

Teva Women's Health, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the recently approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets are now available via prescription in the U.S. for the prevention of pregnancy.

24 Sep 2013

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

Today, the U.S. Food and Drug Administration announced it has approved the use of Plan B One-Step (levonorgestrel) as a nonprescription product for all women of child-bearing potential.

21 Jun 2013

Questions emerge as dust settles surrounding Plan B policy change

News outlets offer day-after coverage of the Obama administration's reversal on the morning-after contraceptive pill.

13 Jun 2013